S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
15 A.I. Trading Opportunities a Day (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
15 A.I. Trading Opportunities a Day (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums

Xencor (XNCR) Stock Forecast, Price & News

$27.69
+0.55 (+2.03%)
(As of 06/2/2023 ET)
Compare
Today's Range
$26.92
$27.70
50-Day Range
$26.05
$29.90
52-Week Range
$19.35
$38.20
Volume
278,925 shs
Average Volume
259,497 shs
Market Capitalization
$1.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.33

Xencor MarketRank™ Forecast

Analyst Rating
Buy
3.09 Rating Score
Upside/​Downside
63.7% Upside
$45.33 Price Target
Short Interest
Bearish
8.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
0.63mentions of Xencor in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$607,254 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($3.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

570th out of 983 stocks

Pharmaceutical Preparations Industry

283rd out of 486 stocks


XNCR stock logo

About Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

XNCR Stock News Headlines

“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Bank of America Begins Coverage on Xencor (NASDAQ:XNCR)
Xencor (NASDAQ:XNCR) Now Covered by StockNews.com
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Wedbush Sticks to Their Buy Rating for Xencor (XNCR)
What 6 Analyst Ratings Have To Say About Xencor
Xencor (XNCR) Set to Announce Earnings on Monday
Xencor Full Year 2022 Earnings: EPS Beats Expectations
See More Headlines

XNCR Price History

XNCR Company Calendar

Last Earnings
5/08/2023
Today
6/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XNCR
Employees
254
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$45.33
High Stock Price Forecast
$59.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+63.7%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Net Income
$-55,180,000.00
Net Margins
-142.32%
Pretax Margin
-141.63%

Debt

Sales & Book Value

Annual Sales
$98.05 million
Book Value
$11.32 per share

Miscellaneous

Free Float
57,390,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
0.76

Key Executives

  • Bassil I. DahiyatBassil I. Dahiyat
    President, Chief Executive Officer & Director
  • John J. Kuch
    Chief Financial Officer & Senior Vice President
  • John R. Desjarlais
    Chief Scientific Officer & Executive VP-Research
  • Nancy Valente
    Chief Development Officer & Executive VP
  • Celia E. Eckert
    Secretary, Senior Vice President & General Counsel













XNCR Stock - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last twelve months. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price forecast for 2023?

11 brokers have issued 1 year price targets for Xencor's stock. Their XNCR share price forecasts range from $36.00 to $59.00. On average, they anticipate the company's share price to reach $45.33 in the next year. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2023?

Xencor's stock was trading at $26.04 at the beginning of the year. Since then, XNCR shares have increased by 6.3% and is now trading at $27.69.
View the best growth stocks for 2023 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) posted its earnings results on Monday, May, 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by $0.27. The biopharmaceutical company had revenue of $18.90 million for the quarter, compared to analysts' expectations of $26.89 million. Xencor had a negative net margin of 142.32% and a negative trailing twelve-month return on equity of 19.41%. The firm's revenue was down 77.9% compared to the same quarter last year. During the same period last year, the business posted $0.39 EPS.

What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (17.43%), FMR LLC (6.22%), Price T Rowe Associates Inc. MD (5.45%), State Street Corp (5.43%), Dimensional Fund Advisors LP (2.56%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert and John J Kuch.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $27.69.

How much money does Xencor make?

Xencor (NASDAQ:XNCR) has a market capitalization of $1.67 billion and generates $98.05 million in revenue each year. The biopharmaceutical company earns $-55,180,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.

How many employees does Xencor have?

The company employs 254 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The official website for the company is www.xencor.com. The biopharmaceutical company can be reached via phone at (626) 305-5900, via email at investors@xencor.com, or via fax at 626-305-0350.

This page (NASDAQ:XNCR) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -